{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:59:37Z","timestamp":1790319577715,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100005003","name":"Baskent \u00dcniversitesi","doi-asserted-by":"publisher","award":["DA24\/11"],"award-info":[{"award-number":["DA24\/11"]}],"id":[{"id":"10.13039\/501100005003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    We aimed to investigate the activity of aztreonam and aztreonam\u2010avibactam combination against gram\u2010negative bacilli producing different types of \u03b2\u2010lactamases. Activity of aztreonam and aztreonam\u2010avibactam against 166 isolates (33 AmpC\u2010producing, 33 ESBL\u2010producing, 66 carbapenemase\u2010producing Enterobacterales, 34 metallo\u2010\u03b2\u2010lactamase\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                    <\/jats:styled-content>\n                    ) from four centers in T\u00fcrkiye was determined using gradient diffusion method. Aztreonam susceptibility rates among AmpC\u2010producing, ESBL\u2010producing and carbapenemase\u2010producing Enterobacterales were 75.8%, 3% and 6.1%, respectively. All AmpC\u2010producing or ESBL\u2010producing Enterobacterales were susceptible to aztreonam\u2010avibactam. ESBL\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                    <\/jats:styled-content>\n                    had significantly higher aztreonam\u2010avibactam MICs compared with ESBL\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>E. coli<\/jats:italic>\n                    <\/jats:styled-content>\n                    .\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>K.\u00a0pneumoniae<\/jats:italic>\n                    <\/jats:styled-content>\n                    carrying\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>CTX<\/jats:italic>\n                      \u2010M\n                    <\/jats:sub>\n                    \u2009+\u2009\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>SHV<\/jats:sub>\n                    \u2009+\u2009\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>TEM<\/jats:sub>\n                    had significantly higher aztreonam\u2010avibactam MICs when compared to those carrying only\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>CTX\u2010M<\/jats:sub>\n                    . Aztreonam\u2010avibactam susceptibility rate among carbapenemase\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                    <\/jats:styled-content>\n                    (100%) was significantly higher than that observed for carbapenemase\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>E. coli<\/jats:italic>\n                    <\/jats:styled-content>\n                    (65%). Metallo\u2010\u03b2\u2010lactamase\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                    <\/jats:styled-content>\n                    had significantly higher aztreonam\u2010avibactam MICs (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    : 16\/96\u2009mg\/L) when compared to metallo\u2010\u03b2\u2010lactamase\u2010producing Enterobacterales (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    : 0.19\/8\u2009mg\/L). Aztreonam\u2010avibactam may be an option for treatment of infections caused by ESBL\u2010producing or AmpC\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                    <\/jats:styled-content>\n                    ,\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>E. coli<\/jats:italic>\n                    <\/jats:styled-content>\n                    and carbapenemase\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                    <\/jats:styled-content>\n                    . However, aztreonam\u2010avibactam resistance may be encountered in a considerable portion of carbapenem\u2010resistant\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>E. coli<\/jats:italic>\n                    <\/jats:styled-content>\n                    isolates. High aztreonam\u2010avibactam MIC values suggest limited in\u00a0vitro activity of aztreonam\u2010avibactam against MBL\u2010producing\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                    <\/jats:styled-content>\n                    isolates in this collection.\n                  <\/jats:p>","DOI":"10.1111\/apm.70265","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:53:02Z","timestamp":1789455182000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Four\u2010Center Study on the Activity of Aztreonam and Aztreonam\u2010Avibactam Combination Against Clinical Isolates of Gram\u2010Negative Bacilli Producing Representatives of Ambler Class A, B, C or D \u03b2\u2010Lactamases"],"prefix":"10.1111","volume":"134","author":[{"given":"Gizem \u0130nce","family":"Ceviz","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology Ba\u015fkent University Faculty of Medicine  Ankara T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8853-3893","authenticated-orcid":false,"given":"Hasan Cenk","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology Ba\u015fkent University Faculty of Medicine  Ankara T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-028X","authenticated-orcid":false,"given":"Aylin \u00dcsk\u00fcdar","family":"G\u00fc\u00e7l\u00fc","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology Ba\u015fkent University Faculty of Medicine  Ankara T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem \u00d6\u011f\u00fc\u00e7","family":"\u015eanl\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Adana Medical and Research Center Ba\u015fkent University Faculty of Medicine  Adana T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem Kurt","family":"Azap","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology Ba\u015fkent University Faculty of Medicine  Ankara T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-4674","authenticated-orcid":false,"given":"Banu","family":"Sancak","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology Hacettepe University Faculty of Medicine  Ankara T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvan Horta\u00e7","family":"\u0130\u015ftar","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology Etlik City Hospital  Ankara T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ba\u015fustao\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology Girne American University Faculty of Medicine  Kyrenia Northern Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1047109"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00472\u201017"},{"key":"e_1_2_11_4_1","unstructured":"European Medicines Agency \u201cEuropean Medicines Agency \u201daccessed 17 March 2026 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emblaveo."},{"key":"e_1_2_11_5_1","unstructured":"US FDA \u201cEmblaveo Prescribing Information \u201daccessed 23 March 2026 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217906Orig1s000lbl.pdf."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00404\u201011"},{"key":"e_1_2_11_7_1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"CLSI","year":"2026"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001592"},{"key":"e_1_2_11_9_1","unstructured":"EUCAST \u201cBreakpoint Tables for Interpretation of MICs and Zone Diameters \u201d(2026) Version 16.0 http:\/\/www.eucast.org."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.12.002"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.7.3129\u20103135.2005"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02050\u201013"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1914"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0732\u20108893(00)00163\u20102"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.01.014"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2024.2316539"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036\u201008"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04191\u201014"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01195\u201018"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03361\u201013"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.04.023"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz468"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2026.106222"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.00184\u201025"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096\u2010023\u201004645\u20102"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf161"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku568"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389\u201017"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad276"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad759"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13060564"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10121638"},{"key":"e_1_2_11_33_1","unstructured":"US FDA \u201c510(k) Substantial Equivalence Determination Decision Summary \u201daccessed 20 August 2026 https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K252114.pdf."}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apm.70265","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apm.70265","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apm.70265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:16:57Z","timestamp":1790317017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apm.70265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/apm.70265"],"URL":"https:\/\/doi.org\/10.1111\/apm.70265","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70265"}}